← SynDRA
RIVOCERANIB
SynDRA canonical compound SYN0037947 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | CSK | CYP3A5 | KDR | KIT | RET |
|---|
| Mechanism of action | RET tyrosine kinase inhibitor |
|---|
All known targets
- KDR
- CSK
- KIT
- RET
- CYP3A5
- MAP3K20
- RIPK3
- SRC
Mechanisms of action (all sources)
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- CSK INHIBITOR
- KIT INHIBITOR
- RET INHIBITOR
- RET tyrosine kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- AAK1
- PDXK
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- NQO2
- NLK
- NEK9
- NEK7
- NEK3
- PDGFRB
- PEBP1
- NEK1
- PFKP
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM1
- PHKG2
- NEK2
- NDUFA13
- PRKCB
- MAPK1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
Cross-references
Synonyms
- apatinib
- apatinib mesylate
- apatinib mesilate
- YN968D1
- Apatinib
- Apatinib free base
- YN968D1 FREE BASE
- N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide
- N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
- 5S371K6132
- N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide
- 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-
- UNII-5S371K6132
- apatinib (in China)
- RIVOCERANIB [INN]
- Rivoceranib (USAN/INN)
- RIVOCERANIB [USAN]
- RIVOCERANIB [WHO-DD]
- GTPL7648
- SCHEMBL1814966
- CHEMBL3186534
- Apatinib free base; YN-968D1
- DTXSID601024366
- AMY21302
- BCP02840
- EX-A1794
- HY-13342A
- MFCD21648511
- NSC772886
- NSC799333
- s5248
- ZINC70466461
- AKOS024464453
- CCG-268625
- DB14765
- DS-7455
- NSC-772886
- NSC-799333
Look up RIVOCERANIB in the interactive SynDRA portal →